Is the risk of lymphoma increased by immunosuppressive therapy in patients with inflammatory bowel disease? The missing link for considering early immunosuppressants;Le risque de lymphome est-il accru par les immunosuppresseurs au cours des maladies inflammatoires chroniques de l'intestin? Le maillon manquant pour légitimer l'immunosuppression précoce

Gastroenterologie Clinique et Biologique

Volumn 28, Issue 3, 2004, Pages 218-220

  Beaugerie, Laurent ^a  

^a HÔPITAL SAINT ANTOINE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE;

CANCER RISK; CONSERVATIVE TREATMENT; CROHN DISEASE; DISEASE ASSOCIATION; DRUG EFFICACY; ENTERITIS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOMA; RISK ASSESSMENT; RISK FACTOR; SHORT SURVEY; TREATMENT OUTCOME;

EID: 1942534037     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0399-8320(04)94886-5     Document Type: Short Survey

References (29)

1. Beaugerie L, Gendre JP. Azathioprine, 6-mercaptopurine, et maladies inflammatoires de l'intestin. Gastroenterol Clin Biol 1990;14:230-40.
2. Present DH, Korelitz BI, Wisch N, Glass JL, Sachar DB, Pasternack BS. Treatment of Crohn's disease with 6-mercaptopurine. A long-term, randomized, double-blind study. N Engl J Med 1980;302:981-7.
3. Lemann M, Bonhomme P, Bitoun A, Messing B, Modigliani R, Rambaud JC, Traitement de la maladie de Crohn par azathioprine ou 6-mercaptopurine. Etude rétrospective de 126 cas. Gastroenterol Clin Biol 1990;14:548-54.
4. Bouhnik Y, Lemann M, Mary JY, Scemama G, Tai R, Matuchansky C, et al. Long-term follow-up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine. Lancet 1996;347:215-9.
5. Feagan BG, Rochon J, Fedorak RN, Irvine EJ, Wild G, Sutherland L, et al. Methotrexate for the treatment of Crohn's disease. The North American Crohn's Study Group Investigators. N Engl J Med 1995;332: 292-7.
6. Feagan BG, Fedorak RN, Irvine EJ, Wild G, Sutherland L, Steinhart AH, et al. A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators. N Engl J Med 2000;342:1627-32.
7. Rutgeerts P. A critical assessment of new therapies in inflammatory bowel disease. J Gastroenterol Hepatol 2002;17 Suppl:S176-85.
8. Levenstein S, Li Z, Almer S, Barbosa A, Marquis P, Moser G, et al. Cross-cultural variation in disease-related concerns among patients with inflammatory bowel disease. Am J Gastroenterol 2001;96:1822-30.
9. Cosnes J, Nion-Larmurier I, Beaugerie L, Gendre JP. Do immunosuppressants have any impact on the need for surgery in Crohn's disease? (abstract) Gastroenterology 2003;124:A10.
10. Hanauer SB. Crohn's disease: step up or top down therapy. Best Pract Res Clin Gastroenterol 2003;17:131-7.
11. Markowitz J, Grancher K, Kohn N, Lesser M, Daum F. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease. Gastroenterology 2000;119:895-902.
12. Lewis JD, Schwartz JS, Lichtenstein GR. Azathioprine for maintenance of remission in Crohn's disease: benefits outweigh the risk of lymphoma. Gastroenterology 2000;118:1018-24.
13. Ardizzone S, Molteni P, Imbesi V, Bollani S, Bianchi Porro G, Molteni F. Azathioprine in steroid-resistant and steroid-dependent ulcerative colitis. J Clin Gastroenterol 1997;25:330-3.
14. Hawthorne AB, Logan RF, Hawkey CJ, Foster PN, Axon AT, Swarbrick ET, et al. Randomised controlled trial of azathioprine withdrawal in ulcerative colitis. BMJ 1992;305:20-2.
15. Hanauer SB, Present DH. The state of the art in the management of inflammatory bowel disease. Rev Gastroenterol Disord 2003;3:81-92.
16. D'Haens G, Lemmens L, Geboes K, Vandeputte L, Van Acker F, Mortelmans L, et al. Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis. Gastroenterology 2001;120:1323-9.
17. Beaugerie L, Penna C. Rectocolite hémorragique: anastomose iléorectale ou iléoanale? Gastroenterol Clin Biol 2000;24:B39-46.
18. Ording Olsen K, Juul S, Berndtsson I, Oresland T, Laurberg S. Ulcerative colitis: female fecundity before diagnosis, during disease, and after surgery compared with a population sample. Gastroenterology 2002;122:15-9.
19. Kinlen LJ, Sheil AG, Peto J, Doll R. Collaborative United Kingdom-Australian study of cancer in patients treated with immunosuppressive drugs. BMJ 1979;2:1461-6.
20. Kinlen LJ. Incidence of cancer in rheumatoid arthritis and other disorders after immunosuppressive treatment. Am J Med 1985;78:44-9.
21. Knowles DM. Immunodeficiency-associated lymphoproliferative disorders. Mod Pathol 1999;12:200-17.
22. Loftus EV, Jr., Sandborn WJ. Lymphoma risk in inflammatory bowel disease: influences of referral bias and therapy. Gastroenterology 2001;121:1239-42.
23. Aithal GP, Mansfield JC. Review article: the risk of lymphoma associated with inflammatory bowel disease and immunosuppressive treatment. Aliment Pharmacol Ther 2001;15:1101-8.
24. Farrell RJ, Ang Y, Kileen P, O'Briain DS, Kelleher D, Keeling PW, et al. Increased incidence of non-Hodgkin's lymphoma in inflammatory bowel disease patients on immunosuppressive therapy but overall risk is low. Gut 2000;47:514-9.
25. Dayharsh GA, Loftus EV, Jr., Sandborn WJ, Tremaine WJ, Zinsmeister AR, Witzig TE, et al. Epstein-Barr virus-positive lymphoma in patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopurine. Gastroenterology 2002;122:72-7.
26. Palli D, Trallori G, Bagnoli S, Saieva C, Tarantino O, Ceroti M, et al. Hodgkin's disease risk is increased in patients with ulcerative colitis. Gastroenterology 2000;119:647-53.
27. Lewis JD, Bilker WB, Brensinger C, Deren JJ, Vaughn DJ, Strom BL. Inflammatory bowel disease is not associated with an increased risk of lymphoma. Gastroenterology 2001;121:1080-7.
28. Blomqvist P, Feltelius N, Lofberg R, Ekbom A. A 10-year survey of inflammatory bowel diseases-drug therapy, costs and adverse reactions. Aliment Pharmacol Ther 2001;15:475-81.
29. Carli PM, Milan C, Lange A, Devilliers E, Guy H, Faivre J. Haematopoietic malignancies in Côte d'Or (France): a population based study. Br J Cancer 1986;53:811-5